
DermWireTV: 2018 Therapeutics and Device Highlights
Monday, December 17, 2018| Acne, , BTL , , Cutanea Life Sciences, , Ortho Dermatologics, , Psoriasis, , Restylane, , Skin Cancer, , Sun Pharmaceutical Industries Ltd ,
2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.

Thursday, March 21, 2019
DermWireTV: Updates from Principia, Sebacia, and Candela
Phase 2 data for from the Believe-PV study for PRN1008 show that the investigational agent from Principia Biopharma reached the primary efficacy measure in pemphigus. Data confirm that Sebacia microparticles confer benefit in the management of acne vulgaris in real-world settings. Candela has rebranded to reflect the unification of the Syneron and Candela brands. Dupixent from Regeneron Pharmaceuticals and Sanofi is now approved to treat atopic dermatitis in patients ages 12 through 17.
Watch Video
Thursday, March 07, 2019
DermWire TV: Annual Meeting Highlights; Ortho Derm's New Cash Pay Model
The annual meeting of the American Academy of Dermatology features updates in medical, surgical, and cosmetic dermatology. Practical Dermatology Chief medical editor Dr. Neal Bhatia highlighted the breadth of coverage at the meeting. DermTube caught up with multiple presenters who shared pearls from the AAD talks, including Diane Berson, MD, Shari Lipner, MD, Seemal Desai, MD, Rajani Katta, MD, and Joel L. Cohen, MD. Ortho Dermatologics launches a new cash pay prescription model. Company president Bill Humphries provides an overview.
Watch Video
Thursday, February 21, 2019
DermWireTV: Guidelines for PsO, SRT; Promising Data from Sienna
Two new guidelines from the American Academy of Dermatology and the National Psoriasis Foundation outline best practices for treating psoriasis, with a focus on comorbidities and biologic treatment. A new retrospective study shows a cure rate above 97 percent among older patients treated with superficial radiation therapy (SRT) for non-melanoma skin cancers in the lower extremities. Now new consensus guidelines suggest that the treatment should be first-line therapy for appropriate non-melanoma skin cancers in certain patients. Topline results from the pivotal trial of SNA-001 show statistically superior results for the topical agent in conjunction with an 810nm diode laser, compared to vehicle plus laser, for light hair.
Watch Video
Wednesday, February 06, 2019
DermWireTV: Approval for Evolus; Remembering Vic Narurkar, MD
The FDA has approved Jeuveau, the lead product from Evolus, Inc. David Moatazedi, President and CEO of Evolus, and Michael Jafar, Chief Marketing Officer at Evolus, comment on market potential for the new product.Twenty-eight percent of physicians say the prior authorization process required by health insurers for certain drugs, tests, and treatments has led to serious or life-threatening events for patients, according results of a survey released by the American Medical Association. The dermatology and aesthetics community is mourning the death of Vic Narurkar, MD, a well-known researcher, author, and lecturer, and a past president of the American Society of Cosmetic Dermatology and Aesthetic Surgery.
Watch Video
Wednesday, January 23, 2019
DermWire TV: Antibiotics and Cosmetic Trends; Seysara Launches
Dermatologists are prescribing fewer antibiotics to manage acne and rosacea. But, the use of antibiotics after surgical procedures is on the rise. More than one third of American adults are considering a cosmetic treatment in 2019, results of a RealSelf survey show. Seysara (sarecycline), a novel tetracycline-derived oral antibiotic, is now commercially available from Almirall for the treatment of acne.
Watch Video
Tuesday, January 08, 2019
DermWireTV: Bristol-Myers Squibb Acquires Celgene, My UV Tracker, More
Bristol-Myers Squibb will acquire Celgene in a cash and stock transaction with an equity value of approximately $74 Billion. Suneva® Medical partners with Healeon Medical, Inc. and Puregraft, LLC to add two new products to its aesthetics portfolio. Unveiled at the 2018 Consumer Electronics Show, the La Roche-Posay My Skin Track UV from L’Oreal is now available in Apple stores in the US and at apple.com. Pulse Biosciences' Nano-Pulse Stimulation technology achieved outstanding clearance rates on sebaceous hyperplasia lesions on the face, new data show.
Watch Video
Monday, December 17, 2018
DermWireTV: 2018 Therapeutics and Device Highlights
2018 saw new approvals and clearances for acne, impetigo, psoriasis, and skin cancer from Ortho Dermatologics, Sun Pharma, Cutanea, and more. Plus, updates for Restylane, new devices from BTL, Cutera, and others.
Watch Video
Thursday, December 06, 2018
DermWire TV: Updates from CSF, PsA Guidelines, Revance Data
Cosmetic Surgery Forum celebrates a decade of success. The meeting, featuring a panel of experts in both medical and cosmetic dermatology, wrapped up on Saturday and is already announcing plans for 2019. When it comes to psoriatic arthritis, prescribers should treat to target, new guidelines from the National Psoriasis Foundation and the American College of Rheumatology conclude. Revance Therapeutics may submit a Biologics License Application for long-acting neuromodulator daxibotulinumtoxinA for Injection, known as RT002, in the first half of next year.
Watch Video
Thursday, November 15, 2018
DermWireTV: Bryhali, Xepi Launches; Epionce's New Facility
Bryhali (halobetasol propionate) 0.01% Lotion from Ortho Dermatologics is now available for the topical treatment of plaque psoriasis in adults. Lawrence J. Green, MD a lead investigator on the Phase 3 studies speaks to DermWireTV. Botanical-based skincare company Epionce has a new 18,500 square foot manufacturing facility in Boise, ID. Younger individuals and females are more likely to use tanning beds and those who do are developing melanoma at an earlier age. Xepi (ozenoxacin) 1% Cream from Cutanea Life Sciences is now available for the treatment of impetigo in adults and in pediatric patients two months of age or older.
Watch Video
Wednesday, November 07, 2018
DermWire TV: Dupixent for Adolescents priority review, Restylane Lyft via cannulas, Hyperhidrosis Awareness
FDA grants priority review for Sanofi's and Regeneron's sBLA for Dupixent (dupilumab) for adolescents. Galderma’s Restylane Lyft is approved for use with a small, blunt-tip cannula for cheek augmentation and the correction of age-related midface contour deficiencies in patients over the age of 21. The Skin Cancer Foundation’s 22nd annual Gala raises $600,000 to support the organization’s educational campaigns, community programs, and research initiatives.November is Hyperhidrosis Awareness Month. The International Hyperhidrosis Society has information at SweatHelp.org.
Watch Video
Thursday, October 25, 2018
DermWireTV: Updates from ASDS and ISHRS
The Annual meeting of the American Society for Dermatologic Surgery (ASDS) gathered experts in dermatologic surgery in Phoenix. Joel L. Cohen, MD and Shannon Humphrey, MD, who received the 2018 ASDS Award for Outstanding Service, discussed effective cosmetic consults. Diane Berson, MD addressed both medical and device-based approaches to managing acne. The 26th World Congress of the International Society of Hair Restoration Surgery (ISHRS) gathered leaders in hair restoration in Hollywood this month. Sharon Keene, MD spoke about the problem of hair loss in women. Nilofer Farjo, MB, ChB, BAO addressed evolving approaches to hair transplantation in patients with scalp psoriasis.
Watch Video
Tuesday, October 09, 2018
DermWireTV: FDA Approvals, Acne Insights, EPI Gets Cloderm
In a flurry of approvals, FDA gives the nod to Almirall's Seysara (sarecycline), Ortho Dermatologics' Bryhali (halobetasol propionate, 0.01%) Lotion, Paratek Pharmaceuticals' Nuzyra (omadacycline), and Regeneron's Libtayo (cemiplimab). Research shows top earners across various fields in the US may share a history of acne, but other data highlight the negative impact of acne on quality of life. EPI Health has acquired the rights to Cloderm Cream, 0.1% and its authorized generic from Promius Pharma, LLC.
Watch Video